3-4 March 2014 a Russian-Norwegian seminar on translational research of the cardiovascular system was hold in Federal Almazov Medical Research Centre. Director of the Centre, RAS Academician Evgeny Shlyakhto and the Dean of Medical Faculty of the University of Oslo Hilde Nebb welcomed the participants of the seminar.
The seminar presentations were devoted to basic and applied research in the field of physiology and pathophysiology of the cardiovascular system, and data translation in clinical practice.
SCIENTIFIC PROGRAM
Day 1, March 3
10.00
Introduction: Hilde Nebb, Dean of Research, Faculty of Medicine, University of Oslo.
Evgeny Shlyakhto, Director, Almazov Centre.
Session 1 (10.10 – 12.30)
1. Guro Valen: An overview of our main research fields (30 min +20 min discussion)
2. Evgeny Shlyakhto: Translational Research in Almazov Centre (20+10 min)
3. Kеre-Olav Stenslokken: Role of exogenous mitochondrial DNA for cardiomyocyte and mitochondrial function (20 + 20 min)
4. Anton Baysa: Role of mitochondrial DNA in myocardial infarction: phosphoproteomics and protein-protein interactions (20 + 20 min)
5. Anna Kostareva: Role of intermediate filaments in mitochondrial Ca oscillations and cardiomyocyte dysfunction (20+20 min)
12.30-13.00 Lunch
Session 2 (13.00-15.30)
6. Jarle Vaage: Valve calcification (overview) – background, molecular biology, possibilities for prevention, new generation of heart valve prostheses (15+15 min)
7. Arkady Rutkovskiy: available methods and models in valve project: newly established co-cultures of cells (20+20 min)
8. Anna Malashicheva: Notch1 gene in endothelial function and EMT (15+15 min)
9. Arkady Rutkovskiy: MicroRNAs: possible role in valve calcification and myocardial protection (15+15 min)
10. Anton Fedorov: MicroRNAs as markers and regulators in myocardial ischemia (15+15 min)
15.30-15.45 Coffee break
Session 3 (15.45-17.45)
11. Michael Galagudza: (presentation of collaborative project): Validation of new Krebs-Henseleit buffer- based heart preservation solutions in the model of prolonged hypothermic rat heart storage (15+15)
12. Jarle Vaage: TGFbeta3: a new player in myocardial protection (1)
13. Arkady Rutkovskiy: TGFbeta3: a new player in myocardial protection (2) (Total for 7 and 8: 20+20 min)
14. Michael Galagudza: Myocardial protection with targeted delivery of cardioprotective agents to ischemic-reperfusion myocardium (20+20 min)
Day 2, March 4
Morning (10-11 a.m.) — visit to the renovated building of the Institute of Experimental Medicine
12.00
Discussion on possible joint projects
Based on the information from day 1, we will discuss possibilities for joint projects.
Hilde Nebb: Some possibilities for financing.
Jarle Vaage: Introduction: Some thoughts, suggestions and possibilities for projects — including how collaboration can take place — practicalities (10-20 min)
Alexandra Konradi: Concluding remarks (10 min)
13.00-13.30 – meeting on the ongoing protocol on ischemic postconditioning in cardiac surgery (J. Vaage, M. Gordeev, A. Bautin, M. Galagudza)